CGEM NASDAQ
Credit Risk of going bust: lower than 76% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Cullinan Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.1M against a stock market value of $912.0M.
Distance to default 8.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $702K (short-term plus half of long-term), stock volatility 78.2%; Altman Z'' 3.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Cambridge, MA 02142
US
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Michaelson Jennifer | S-Sale | 8,000 | $21.57 | 2026-09-08 |
| Michaelson Jennifer | M-Exempt | 30,000 | $4.30 | 2026-08-13 |
| Michaelson Jennifer | S-Sale | 30,000 | $20.26 | 2026-08-13 |
| Michaelson Jennifer | M-Exempt | 30,000 | $4.30 | 2026-08-13 |
| Michaelson Jennifer | M-Exempt | 4,000 | $4.30 | 2026-07-06 |